
    
      Phase 4, multi-center, randomized, double-blind, placebo-controlled, parallel group study.
      All subjects that meet the baseline criteria will be randomized in a 1:1 ratio into VESIcareÂ®
      (solifenacin succinate) or placebo group.

      The study duration consists of a screening period which includes a minimum of a 14 day
      treatment free wash-out period. Subjects meeting the baseline criteria will have a 12 week
      treatment period. Maximum total study duration is 15 weeks: 2 3 week screening / washout
      period; 12 week double-blind treatment.

      Primary efficacy will be based on OAB-q symptom bother score.
    
  